Exact Mass: 554.0667

Exact Mass Matches: 554.0667

Found 54 metabolites which its exact mass value is equals to given mass value 554.0667, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Ceftriaxone

(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C18H18N8O7S3 (554.0461)


Ceftriaxone is only found in individuals that have used or taken this drug. It is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. [PubChem]Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

cefsulodin sodium

cefsulodin sodium

C22H19N4O8S2. Na (554.0542)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D02005

   

8-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one

8-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one

C30H18O11 (554.0849)


   

Hydroxyamentoflavone

Hydroxyamentoflavone

C30H18O11 (554.0849)


   
   

Cefatriaxone

7-[2-(2-Imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C18H18N8O7S3 (554.0461)


   

3-Hydroxyamentoflavone

3-Hydroxyamentoflavone

C30H18O11 (554.0849)


   

Moghatin

(+)-2-(3,4-Dihydroxyphenyl)-5,5,7,7-tetrahydroxy-2-(4-hydroxyphenyl)-[8,8-bi-4H-1-benzopyran]-4,4-dione

C30H18O11 (554.0849)


   

3-Desoxydicranolomin

6-[6-(5,7-Dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2,3-dihydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one

C30H18O11 (554.0849)


   

5-Hydroxyamentoflavone

5-Hydroxyamentoflavone

C30H18O11 (554.0849)


   
   

5-Hydroxyrobustaflavone

5-Hydroxyrobustaflavone

C30H18O11 (554.0849)


   
   

Amentoflavone

Amentoflavone

C30H18O11 (554.0849)


   
   

Antibiotic DK 7814B

Antibiotic DK 7814B

C26H18O14 (554.0697)


   
   

Aurantioskyrin

Aurantioskyrin

C30H18O11 (554.0849)


   

(8aR)-13-amino-11-chloro-4t,15,16-trihydroxy-1t-methoxy-12-methyl-(8ar)-1,2,3,4,8a,13-hexahydro-9H-chromeno[3,2:6,7][1,3]dioxino[4,5,6:4,5]naphtho[2,1-g]isoquinoline-5,14-dione|4-Chlor-albofungin|Chlor-Albofungin

(8aR)-13-amino-11-chloro-4t,15,16-trihydroxy-1t-methoxy-12-methyl-(8ar)-1,2,3,4,8a,13-hexahydro-9H-chromeno[3,2:6,7][1,3]dioxino[4,5,6:4,5]naphtho[2,1-g]isoquinoline-5,14-dione|4-Chlor-albofungin|Chlor-Albofungin

C27H23ClN2O9 (554.1092)


   

3,4,4,5,5,7,7-Heptahydroxy-3,8-biflavone

3,4,4,5,5,7,7-Heptahydroxy-3,8-biflavone

C30H18O11 (554.0849)


   
   

Ridiculuflavone A

Ridiculuflavone A

C30H18O11 (554.0849)


   

Ceftriaxone

Ceftriaxone

C18H18N8O7S3 (554.0461)


A cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Hydroxyamentoflavone

Hydroxyamentoflavone

C30H18O11 (554.0849)


   

[4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)phenyl]methanol

[4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)phenyl]methanol

C17H11F17O (554.0538)


   

2,4,5,8,11,12,14,17-octachloroicosane

2,4,5,8,11,12,14,17-octachloroicosane

C20H34Cl8 (554.0169)


   

Zolasartan

3-[[3-bromo-2-[2-(2H-tetrazol-5-yl)phenyl]-1-benzofuran-5-yl]methyl]-2-butyl-5-chloroimidazole-4-carboxylic acid

C24H20BrClN6O3 (554.0469)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers

   

1 4-DIIODO-2 5-DIOCTYLBENZENE

1 4-DIIODO-2 5-DIOCTYLBENZENE

C22H36I2 (554.0906)


   

1,4-Bis(2-ethylhexyl)-2,5-diiodobenzene

1,4-Bis(2-ethylhexyl)-2,5-diiodobenzene

C22H36I2 (554.0906)


   
   

1,1-Bis(diphenylphosphino)ferrocene

1,1-Bis(diphenylphosphino)ferrocene

C34H28FeP2 (554.1016)


   

Distannoxane,1,1,3,3-tetrabutyl-1,3-dichloro-

Distannoxane,1,1,3,3-tetrabutyl-1,3-dichloro-

C16H36Cl2OSn2 (554.0187)


   
   
   

[(8R,9S,10R,13S,14S,17R)-17-acetyl-6-(dibromomethylidene)-10,13-dimethyl-3-oxo-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate

[(8R,9S,10R,13S,14S,17R)-17-acetyl-6-(dibromomethylidene)-10,13-dimethyl-3-oxo-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate

C25H32Br2O4 (554.0667)


   

N-{7-Cyano-6-[4-Fluoro-3-({[3-(Trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-Benzothiazol-2-Yl}cyclopropanecarboxamide

N-{7-Cyano-6-[4-Fluoro-3-({[3-(Trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-Benzothiazol-2-Yl}cyclopropanecarboxamide

C27H18F4N4O3S (554.1036)


TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.

   

1-[3-[(5-bromo-2-pyridinyl)-[(3,4-dichlorophenyl)methyl]amino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea

1-[3-[(5-bromo-2-pyridinyl)-[(3,4-dichlorophenyl)methyl]amino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea

C22H25BrCl2N6S (554.0422)


   

cefsulodin sodium

cefsulodin sodium

C22H19N4NaO8S2 (554.0542)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

   

Ceftriaxone-d3DisodiumSalt

Ceftriaxone-d3DisodiumSalt

C18H18N8O7S3 (554.0461)


   

1,2-dibutyryl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate)

1,2-dibutyryl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate)

C17H32O16P2 (554.1166)


A 1-phosphatidyl-1D-myo-inositol 5-phosphate in which both phosphatidyl acyl groups are specified as butanoyl.

   
   

GSK837149A

GSK837149A

C23H22N8O5S2 (554.1155)


GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer[1][2].

   

2'-(3,4-dihydroxyphenyl)-5,5',7,7'-tetrahydroxy-2-(4-hydroxyphenyl)-[3,6'-bichromene]-4,4'-dione

2'-(3,4-dihydroxyphenyl)-5,5',7,7'-tetrahydroxy-2-(4-hydroxyphenyl)-[3,6'-bichromene]-4,4'-dione

C30H18O11 (554.0849)


   

6-[6-(5,7-dihydroxy-4-oxochromen-2-yl)-2,3-dihydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one

6-[6-(5,7-dihydroxy-4-oxochromen-2-yl)-2,3-dihydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one

C30H18O11 (554.0849)


   

8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2,3-dihydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one

8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2,3-dihydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one

C30H18O11 (554.0849)


   

4-bromo-n-[3-(2-imino-1,3-dihydroimidazol-4-yl)-2-(2-imino-5-oxo-4-{8-oxo-1h,5h,6h,7h-pyrrolo[2,3-c]azepin-4-ylidene}imidazolidin-1-yl)propyl]-1h-pyrrole-2-carboxamide

4-bromo-n-[3-(2-imino-1,3-dihydroimidazol-4-yl)-2-(2-imino-5-oxo-4-{8-oxo-1h,5h,6h,7h-pyrrolo[2,3-c]azepin-4-ylidene}imidazolidin-1-yl)propyl]-1h-pyrrole-2-carboxamide

C22H23BrN10O3 (554.1138)


   

6-amino-8-chloro-3,24,28-trihydroxy-21-methoxy-7-methyl-14,16,19-trioxa-6-azaheptacyclo[15.11.1.0²,¹¹.0⁴,⁹.0¹³,²⁹.0¹⁸,²⁷.0²⁰,²⁵]nonacosa-1(29),2(11),3,7,9,17,20(25),27-octaene-5,26-dione

6-amino-8-chloro-3,24,28-trihydroxy-21-methoxy-7-methyl-14,16,19-trioxa-6-azaheptacyclo[15.11.1.0²,¹¹.0⁴,⁹.0¹³,²⁹.0¹⁸,²⁷.0²⁰,²⁵]nonacosa-1(29),2(11),3,7,9,17,20(25),27-octaene-5,26-dione

C27H23ClN2O9 (554.1092)


   

8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,6,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one

8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,6,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one

C30H18O11 (554.0849)


   

6-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2,3-dihydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one

6-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2,3-dihydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one

C30H18O11 (554.0849)


   

2-(3,4-dihydroxyphenyl)-5,5',7,7'-tetrahydroxy-2'-(4-hydroxyphenyl)-[8,8'-bichromene]-4,4'-dione

2-(3,4-dihydroxyphenyl)-5,5',7,7'-tetrahydroxy-2'-(4-hydroxyphenyl)-[8,8'-bichromene]-4,4'-dione

C30H18O11 (554.0849)


   

(3r,4ar,10as)-3-bromo-4a-chloro-6,8-dihydroxy-2,2,7-trimethyl-10a-{[(1s,2s,4r)-1,3,3-trimethyl-7-oxabicyclo[2.2.1]heptan-2-yl]methyl}-3h,4h-naphtho[2,3-b]pyran-5,10-dione

(3r,4ar,10as)-3-bromo-4a-chloro-6,8-dihydroxy-2,2,7-trimethyl-10a-{[(1s,2s,4r)-1,3,3-trimethyl-7-oxabicyclo[2.2.1]heptan-2-yl]methyl}-3h,4h-naphtho[2,3-b]pyran-5,10-dione

C26H32BrClO6 (554.1071)


   

8-[3-(5,7-dihydroxy-4-oxochromen-2-yl)-5-hydroxyphenyl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one

8-[3-(5,7-dihydroxy-4-oxochromen-2-yl)-5-hydroxyphenyl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one

C30H18O11 (554.0849)


   

4-bromo-n-[(2s)-2-{4-[(4z)-8-hydroxy-1h,5h,6h-pyrrolo[2,3-c]azepin-4-ylidene]-2-imino-5-oxoimidazolidin-1-yl}-3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-1h-pyrrole-2-carboxamide

4-bromo-n-[(2s)-2-{4-[(4z)-8-hydroxy-1h,5h,6h-pyrrolo[2,3-c]azepin-4-ylidene]-2-imino-5-oxoimidazolidin-1-yl}-3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-1h-pyrrole-2-carboxamide

C22H23BrN10O3 (554.1138)


   

(6r,7r)-7-{[(2z)-1-hydroxy-2-(2-imino-3h-1,3-thiazol-4-yl)-2-(methoxyimino)ethylidene]amino}-3-{[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

(6r,7r)-7-{[(2z)-1-hydroxy-2-(2-imino-3h-1,3-thiazol-4-yl)-2-(methoxyimino)ethylidene]amino}-3-{[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C18H18N8O7S3 (554.0461)